Andamertinib 治疗铂类化疗或免疫治疗后 EGFR 外显子20插入突变晚期 NSCLC:2期 KANNON 研究结果
KANNON 是一项2期、多中心、单臂研究,评估 andamertinib 240 mg 每日一次口服治疗铂类化疗或免疫治疗后进展的 EGFR ex20ins 突变晚期 NSCLC 患者。92例患者确认 ORR 为 42.7%,DCR 为 86.5%,中位 PFS 为 6.2 个月,安全性可控。
要点
- 经治 EGFR ex20ins 突变晚期 NSCLC 中确认 ORR 达 42.7%。
- 中位 PFS 为 6.2 个月,中位 OS 未达到,12个月生存率 70.5%。
- ≥3级治疗相关不良事件发生率 40.2%,最常见为腹泻和皮疹。
核心结论
- Andamertinib 240 mg 每日一次在经治 EGFR ex20ins 突变晚期 NSCLC 中显示出疗效且安全性可控。
研究设计与样本
- 2期、多中心、单臂 KANNON 研究(NCT06015503),纳入92例铂类化疗或免疫治疗后进展的局部晚期或转移性 EGFR ex20ins 突变 NSCLC 患者。
- 患者口服 andamertinib 240 mg 每日一次,28天为一周期;主要终点为独立评审确认的 ORR。
主要发现
- 确认 ORR 为 42.7%(95%CI 32.4-53.0),疾病控制率为 86.5%,中位缓解持续时间为 8.7 个月(95%CI 5.65-11.96)。
- 中位随访 15.4 个月(范围 0.4-20.5)时,中位 PFS 为 6.2 个月(95%CI 4.63-7.85),中位 OS 未达到(95%CI 13.93 个月至不可估计),12个月生存率为 70.5%。
- 38例脑转移患者的全身确认 ORR 为 47.4%(95%CI 31.5-63.2)。
- ≥3级治疗相关不良事件发生率为 40.2%,最常见为腹泻(12.0%)和皮疹(7.6%);未报告间质性肺病或≥3级 QT 间期延长。
临床怎么用
- 对于铂类化疗或免疫治疗后进展的 EGFR ex20ins 突变晚期 NSCLC,andamertinib 240 mg 每日一次可作为候选治疗选择。
- 治疗期间需关注腹泻和皮疹等不良事件,但未报告间质性肺病或≥3级 QT 间期延长。
局限性
- 本研究为单臂2期研究,未设对照组,结论需随机对照研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate andamertinib, a selective and irreversible tyrosine kinase inhibitor, in pretreated advanced EGFR exon 20 insertion (ex20ins)-mutant NSCLC. METHODS: In the phase 2, multicenter, single-arm KANNON study (NCT06015503), patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who had progressed after platinum-based chemotherapy or immunotherapy received oral andamertinib 240 mg once daily in 28-day cycles. The primary end point was the confirmed objective response rate (ORR) assessed by independent review. RESULTS: A total of 92 patients were enrolled and received daily 240 mg andamertinib, with nearly 30 different exon20ins subtypes included. The confirmed ORR was 42.7% (95% confidence interval [CI], 32.4-53.0), with a disease control rate of 86.5% and a median duration of response of 8.7 months (95% CI, 5.65-11.96). As of September 6, 2025, with a median follow-up of 15.4 (range, 0.4-20.5) months, the median progression-free survival was 6.2 months (95% CI, 4.63-7.85) and median overall survival was not reached (95% CI, 13.93 mo to not estimable), with a 12-month survival rate of 70.5%. Among 38 patients with brain metastasis, the systemic confirmed ORR was 47.4% (95% CI, 31.5-63.2). Grade more than or equal to 3 treatment-related adverse events occurred in 40.2% of patients, and the most frequent events were diarrhea (12.0%) and rash (7.6%). No interstitial lung disease or grade more than or equal to 3 QT prolongation was reported. CONCLUSIONS: Andamertinib at 240 mg once daily demonstrated efficacy with a manageable safety profile in previously treated patients with EGFR ex20ins-mutant NSCLC.
引用
- Yang JJ, Mu Y, Wang ZH, et al. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study. J Thorac Oncol. 2025. PMID: 41248848. doi:10.1016/j.jtho.2025.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。